glp 1 drug makers Market Overview: GLP-1 Agonists and the Obesity Market | Blog The next phase of the

The year 2026 is expected to determine how quickly these treatments move from niche adoption to broader access across the country

Overall pipeline momentum is unprecedented for metabolic disease

HbA1c measures the average blood sugar levels over the past three months, corresponding to the average lifespan of red blood cells (RBCs) and indicating the extent to which the RBCs are "sugar-coated." For reference, the American Diabetes Association (ADA) advises that the target A1C for most adults with diabetes should be below 7%

In contrast, Eli Lilly has faced supply issues that have affected the availability of ZEPBOUND

Out-of-pocket expenses also vary based on which GLP-1 medication youve been prescribed